Natroba spinosad: Phase II data

A Phase II trial in 122 patients with active lice infestations showed that a single application of 0.5% or 0.9% Natroba met the co-primary endpoints of a significantly greater proportion of patients who were free of live lice and/or viable nits at day 7 (93% and 92%, respectively, vs. 49%, p<0.0001 for both) and at day 14 post-treatment vs. placebo (83% and 86%, respectively, vs. 26%, p<0.0001 for both). On secondary endpoints, re-infestation rates between day 7 and 14 for low- and high-dose Natroba were 11% and 6%, respectively, vs. 50% for placebo. No serious adverse events were reported. Data were presented at the American Academy of Pediatrics meeting in Boston. ...